EpiCept Corporation (NASDAQ: EPCT), a specialty pharmaceutical company, is focused on meeting unmet medical needs in cancer treatment and pain management. The company has approval from the European Commission to use Ceplene for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Additionally, EpiCept is utilizing its biopharmaceutical discovery capabilities for the discovery and advancement of apoptosis inducers. For further information, visit the Company’s web site at www.epicept.com.
- 18 years ago
QualityStocks
EpiCept Corporation (NASDAQ: EPCT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection
HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored,…
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Advancing Multi-Pronged Growth Strategy Across Beacon Mill and Swanson Gold Project
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising. LaFleur…
-
QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) and Department of Commerce Sign Letter of Intent for $100 Million in CHIPS and Science Act Funding to Accelerate U.S. Leadership in Quantum Computing
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), the only dual-platform quantum computing company providing both annealing…